Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus Inc. (NASDAQ: AGEN) announced that data from two Phase 2 trials of balstilimab, both alone and in combination with zalifrelimab, will be presented at the European Society of Medical Oncology (ESMO) Conference on September 18, 2020. Dr. David O'Malley from Ohio State University will present the findings. The company remains on track to initiate a rolling Biologics License Application (BLA) submission for balstilimab monotherapy this quarter and aims to complete a data packet for the combination therapy by year-end.
Agenus Inc. (NASDAQ: AGEN) released its second quarter 2020 financial results, reporting a net loss of $48 million ($0.28 per share) compared to a loss of $52 million ($0.38 per share) in the same period last year. The company ended Q2 with a cash balance of $79 million, up from $62 million at the end of 2019. Agenus announced advancements in its clinical pipeline, including the initiation of the balstilimab BLA filing and promising results from its combo trials. For the first half of 2020, total revenue reached $42 million, down from $96 million in 2019.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, will present on Targeting Myeloid Cells in the Tumor Microenvironment at the William Blair Biotech Focus Conference 2020 on August 4, 2020, from 11:00 AM to 12:00 PM. The presentation aims to highlight innovative immuno-oncology strategies targeting the tumor microenvironment. Agenus, based in Lexington, MA, focuses on developing therapies to enhance immune responses against cancers and infections, utilizing advanced antibody and vaccine platforms.
Agenus Inc. (NASDAQ: AGEN) announced it will update its pipeline and financial results for Q2 2020 on August 6, 2020. The video conference call will review key topics including registration strategies for balstilimab and zalifrelimab, progress with Betta Pharmaceuticals in China, and the clinical advancement of AGEN1181. Additionally, the company will discuss breakthroughs in allogeneic iNKT cells for COVID-19 and cancer, along with updates on AGEN1223 and AGEN2373. The financial results will provide insight into the company’s fiscal health and future outlook.
Agenus Inc. (NASDAQ: AGEN) has secured a $20 million equity investment from Betta Pharmaceuticals, bringing total funding to $35 million. The investment is part of a broader immuno-oncology partnership, granting Betta exclusive rights for the development of Agenus' balstilimab and zalifrelimab in Greater China, with potential milestones of up to $100 million and royalties on net sales. Balstilimab is set for a BLA filing this year, having received Fast Track designation from the US FDA, positioning the company for significant growth.
Agenus (NASDAQ: AGEN), an immuno-oncology company, announced that Dr. Jennifer Buell and Dr. Manuel Hidalgo will discuss allogeneic iNKT cell therapy for infectious diseases at the B. Riley Virtual Infectious Disease Summit on July 21, 2020, from 3:00 PM to 4:00 PM ET. The panel, titled Pursuing Curative Cell Therapy Approaches, will feature AgenTus Therapeutics, a subsidiary of Agenus, alongside other biotech companies. The discussion will revolve around advancements in cell therapy, including AGENT-797, an early iNKT cell therapy aimed at enhancing the immune system's response to cancer.
Agenus Inc. (NASDAQ: AGEN) presented significant findings on its anti-CTLA-4 therapy, AGEN1181, during the AACR 2020 Virtual Annual Meeting. The therapy has exhibited promising clinical activity in early trials and demonstrated curative responses in preclinical models resistant to anti-PD-1. Dr. Antoine Tanne highlighted the potential of combining AGEN1181 with allogeneic cell therapies to enhance treatment effectiveness against solid tumors. The presentation aimed to expand the therapeutic use of immunotherapy in cancer treatment.
Agenus Inc. (NASDAQ: AGEN) announced a collaboration with Betta Pharmaceuticals for the exclusive development and commercialization of balstilimab and zalifrelimab in Greater China. The deal includes $35 million, consisting of $15 million in cash and a $20 million equity investment, along with up to $100 million in milestone payments and royalties on sales. Balstilimab has received Fast Track designation from the US FDA for cervical cancer treatment. Both companies aim to leverage their strengths to address significant patient needs in China.
Agenus Inc. (NASDAQ: AGEN) announced participation in the Raymond James Virtual Human Health Innovation Conference on June 17, 2020. Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, CTO of Agenus, will discuss advancements in cell therapy from 12:00 PM to 12:50 PM ET. This panel will cover the evolution of cell therapy, particularly focusing on treatments for cancer, including new allogeneic therapies. Agenus aims to harness the immune system's power against cancer through innovative therapies and collaborations.
Agenus Inc. (NASDAQ: AGEN) will have Dr. Jennifer Buell present an update on the company’s progress during the Raymond James Virtual Human Health Innovation Conference on June 18, 2020, from 4:20 PM to 4:50 PM ET. The event will include one-on-one investor meetings. Agenus is focused on immuno-oncology, developing immune checkpoint antibodies, adoptive cell therapies, and cancer vaccines to enhance patient outcomes. For further details, the presentation can be accessed via a webcast at this link.